Resources Antibody Industry Trends Week 2, Mar 2024: The Battle Against Cancer

Week 2, Mar 2024: The Battle Against Cancer

Biointron 2024-03-12 Read time: 3 mins
Image credit: DOI: 10.3390/cancers16040800

In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects, have reshaped treatment approaches across various medical domains. From monospecific human antibodies like avelumab for Merkel cell carcinoma, to bispecific murine antibodies like blinatumomab for acute lymphoblastic leukemia, therapeutic antibodies are highly valuable in treating cancer, given the unique ability of antibodies to directly target tumor cells while concurrently eliciting enduring anti-tumor immune responses.

Just this week, the FDA approved Opdivo (nivolumab, a monoclonal antibody) in combination with the chemotherapies cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. Nivolumab is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway.

Also this week, an insightful review by Klein et al. describes the present and future of bispecific antibodies for cancer therapy, including bsAb-mediated dual modulators of signalling pathways, tumour-targeted receptor agonists, bsAb-drug conjugates, bispecific T cell, natural killer cell and innate immune cell engagers, and bispecific checkpoint inhibitors and co-stimulators. The next-generation bsAbs also being researched include trispecifics, bsAb prodrugs, bsAbs that induce degradation of tumour targets and bsAbs acting as cytokine mimetics.

Besides mAbs and bsAbs, antibody-drug conjugates (ADCs), are still hot in research. Last month, two reviews were published focusing on ADCs against breast cancer. The review by Zimmerman et al. focuses on HER2-targeted ADCs for breast cancer, as HER2 is amplified or overexpressed in about 20% of breast cancer cases. Since patients can often be resistant to treatment with chemotherapy in combination with mAbs like trastuzumab and pertuzumab, ADCs may represent a better-tolerated and more effective therapeutic.

Meanwhile, the review by Monteiro et al. provides an in-depth analysis of the clinical data on ADCs, particularly on pivotal clinical trials that assess the efficacy of ADCs in diverse breast cancer settings. Most interestingly, the future outlook includes personalized ADCs, involving tailored combinations of antibodies, linkers, and payloads based on individual patient tumor antigens and other characteristics to overcome resistance mechanisms.

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Antibody drugs for diabetes typically target specific molecules involved in the regulation of blood sugar levels or the immune response against insulin-producing cells, or specific hormones or receptors involved in glucose metabolism. For instance, teplizumab (Tzield), targets CD3 on T cells, thus deactivating immune cells which attack β-cells.

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.